Evotec Expands Neuroscience Collaboration with Bristol Myers

  • Bristol Myers Squibb & Co BMY has expanded its neuroscience collaboration with Evotec SE EVTCY to include a new cell type.
  • Related: Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate.
  • The expansion has triggered a payment of $9 million to Evotec.
  • The collaboration was initiated in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. 
  • The collaboration pursues an approach to discovering and developing novel medicines by leveraging Evotec's iPSC platform using patient-derived disease models.
  • The latest expansion will enable the companies to investigate the root causes of many neurodegenerative diseases in a cell type-specific fashion using cells directly derived from patients. 
  • In addition, molecular disease signatures will be used to define detailed molecular disease phenotypes using Evotec's panomics platform, EVOpanOmics & EVOpanHunter.
  • Price Action: EVTCY stock closed at $90.38 on Thursday, while BMY stock is down 0.77% at $58.56 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!